Navigation Links
Spectral appoints new board member
Date:8/13/2009

TORONTO, Aug. 13 /PRNewswire-FirstCall/ - Spectral Diagnostics Inc. (TSX:SDI, a company developing products for the treatment of sepsis, today announced the appointment of Dr. Michael Cross to the Company's Board of Directors. Dr. Cross is Vice President of Investments at GrowthWorks Capital, one of Canada's leading venture capital management companies.

"Dr. Cross will be a valuable addition to the Board, bringing experience from both the life sciences' industry and the investment perspective," said Dr. Paul Walker, President and CEO of Spectral. "As a significant shareholder of Spectral, GrowthWorks' continued support is important as we prepare to initiate our registration trial for Toraymyxin(TM) in the US and evaluate different strategic options for this significant commercial opportunity."

Dr. Cross brings more than 20 years of life sciences, venture capital and biotechnology industry experience to the Spectral Board. At GrowthWorks, he is responsible for identifying private and public equity investment opportunities in the life sciences area and he serves on the boards of a number of public and private life sciences companies. Prior to joining GrowthWorks, Dr. Cross has held senior management positions at MDS Proteomics, MDS Capital and Viventia Biotech.

About Spectral Diagnostics

Spectral is a leader in the battle against sepsis. Spectral's lead product is its Endotoxin Activity Assay (EAA(TM)), the only FDA cleared assay for the measurement of endotoxin. With the growing awareness for the role of endotoxemia in sepsis and the increasing number of therapies being developed for this indication, Spectral is well-positioned to drive the adoption of the EAA(TM), which can be used to identify patients, enable therapeutics and monitor treatment. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for Toraymyxin(TM), a therapeutic for the treatment of sepsis that removes endotoxin from the bloodstream. Spectral will seek FDA approval for Toraymyxin(TM) and intends to commercialize the product together with EAA(TM). Spectral is listed on TSX under the symbol SDI.

Forward-looking statement

Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of Spectral and anticipated events or results, are assumptions based on beliefs of Spectral's senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue R D projects, the successful and timely completion of clinical studies, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities as well as general economic, market and business conditions, and could differ materially from what is currently expected.

    The TSX has not reviewed and does not accept responsibility for the
    adequacy or accuracy of this statement.


'/>"/>
SOURCE Spectral Diagnostics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Spectral partner launches EAA(TM) Rapid Sepsis Diagnostic in Germany
2. US Patent and Trademark Office Allows CRis Patent Application for Spectral Imaging of Deep Tissue
3. CRi Announces Nuance 2, the Next-Generation Multispectral Imaging System for Brightfield and Fluorescent-Based Microscopy
4. Spectral announces data on the clinical utility of EAA(TM) to be presented at 12th Annual Critical Care for Endotoxemia Conference in Japan
5. Spectral appoints Anthony Bihl to Board of Directors
6. Spectral announces 2007 financial results
7. Spectral announces new findings on the effectiveness of EAA(TM)/Toraymyxin(TM) at the 28th International Symposium on Intensive Care and Emergency Medicine
8. Spectrals EAA(TM) to be used in Phase III study for a sepsis anti-endotoxin therapy
9. Spectral and Toray expand collaboration to include new geographic territories
10. Spectral announces presentation of data on improving sepsis patient management with EAA(TM) and Toraymyxin(TM) combination
11. Spectral announces continuing support for the combination of EAA(TM) and anti-endotoxin therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... September 20, 2017 , ... ... the effects of exoskeleton-assisted walking on gait parameters and neuromuscular activity in ... adaptations during a robotic powered exoskeleton assisted walking session" (doi:10.1080.10790268.2017.1314900) was epublished ...
(Date:9/20/2017)... , ... September 20, 2017 , ... ... focused on molecular manufacturing and other transformative technologies, announced the winners for the ... and the other for Theory in nanotechnology/molecular manufacturing. , Established in 1993 and ...
(Date:9/19/2017)... (PRWEB) , ... September 19, 2017 , ... ... and accurately automates the most dangerous step of sample prep for metals digestion—the ... to provide automation at an affordable price. The system is ideal for any ...
(Date:9/19/2017)... , ... September 19, 2017 , ... ... largest group of funded early-stage tech companies. “Grit” author Angela Duckworth and her ... joining the ic@3401 community is Cooley, an international law firm with decades of ...
Breaking Biology Technology:
(Date:4/11/2017)... , April 11, 2017 No two ... researchers at the New York University Tandon School ... Engineering have found that partial similarities between prints ... used in mobile phones and other electronic devices ... The vulnerability lies in the fact that ...
(Date:4/5/2017)... LONDON , April 4, 2017 KEY ... is anticipated to expand at a CAGR of 25.76% ... neurodegenerative diseases is the primary factor for the growth ... full report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The ... of product, technology, application, and geography. The stem cell ...
(Date:3/30/2017)... Trends, opportunities and forecast in this market ... (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, vein ... use industry (government and law enforcement, commercial and retail, ... others), and by region ( North America ... Pacific , and the Rest of the World) ...
Breaking Biology News(10 mins):